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ABSTRACT  
The self-assembling processes underlining the capabilities of facially differentiated 
(“Janus”) polycationic amphiphilic cyclodextrins (paCDs) as non-viral gene 
nanocarriers have been investigated by a pluridisciplinary approach. Three 
representative Janus paCDs bearing a common tetradecahexanoyl multitail domain at 
the secondary face and differing in the topology of the cluster of amino groups at the 
primary side were selected for this study. All of them compact pEGFP-C3 plasmid 
DNA and promote transfection in HeLa and MCF-7 cells, both in absence and in 
presence of human serum. The electrochemical and structural characteristics of the 
paCD-pDNA complexes (CDplexes) have been studied by using zeta potential, DLS, 
SAXS, and cryo-TEM. paCDs and pDNA, when assembled in CDplexes, render 
effective charges that are lower than the nominal ones. The CDplexes show a self-
assembling pattern corresponding to multilamellar lyotropic liquid crystal phases, 
characterized by a lamellar stacking of bilayers of the CD-based vectors with anionic 
pDNA sandwiched among them. When exposed to human serum, either in the absence 
or in the presence of pDNA, the surface of the cationic CD-based vector becomes 
coated by a protein corona (PC) whose composition has been analysed by nanoLC-
MS/MS. Some of the CDplexes herein studied showed moderate-to-high transfection 
levels in HeLa and MCF-7 cancer cells combined with moderate-to-high cell viabilities, 
as determined by FACS and MTT reduction assays. The ensemble of data provides a 
detail picture of the paCD-pDNA-PC association processes and a rational base to 
exploit the protein corona for targeted gene delivery on future in vivo applications. 
 
KEYWORDS: CDplexes, effective charge ratio, multilamellar phases, cellular 
transfection, cytotoxicity, protein corona 
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1. Introduction 
Nucleic acids (DNA or RNA) have become in the last decade an attractive source of 
therapeutic agents [1]. The interplay of a direct structure-activity relationship and a 
highly specific mode of action theoretically permit exploiting the cellular machinery in a 
predictable fashion to either stimulate or silence the expression of virtually any protein, 
with reduced toxicity and fewer side effects as compared with classical drugs. This is 
the basis of gene therapy (GT), an exciting branch of medicine that tries to cure diseases 
(genetic, neurologic, cardiovascular, infectious, or carcinogenic, etc.) at a molecular 
level, by repairing damaged cellular DNA, either by introducing (by means of a plasmid 
DNA) and expressing a copy of the affected or missing gene into the cells [2-8] or by 
inserting a small interfering RNA (siRNA) to silence and stop the expression of an 
abnormal gene, responsible of the cell disorder [9-12]. Both approaches, either that one 
based on plasmid DNAs or on siRNAs, constitute nowadays the main strategies of GT 
on seeking for effectively restore healthy cell functioning.  
Conventional drugs consist of bioactive species and a carrier, the former being 
normally the key of the design strategies. However, in the case of biomolecular drugs, 
such as nucleic acids, the carrier becomes a decisive protagonist. In the free state, 
nucleic acids are easily degraded by nucleases in biological fluids [13,14], and their 
membrane-crossing abilities and cellular uptake are seriously limited by their negative 
charge, inherently large size, and rigidity [15]. Formulation with appropriate delivery 
systems is thus essential for nucleic acids to overcome the physiological barriers, reach 
the target in a fully functional form and carry out the designed therapeutic function. 
Viral gene vectors [16,17] were first developed towards this end due to their high 
effectiveness. Yet, the use of viral vectors bear inherent risks, including immunogenicity 
and oncogenicity, which has boosted research on the design, synthesis, and 
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characterization of non-viral carriers that may combine high transfection efficiencies 
with low cytotoxicity levels [18,19]. In addition, for in vivo applications, these vectors 
must remain stable in the presence of blood or serum and, ideally, should be amenable 
to surface decoration with selective groups in order to recognize the target cells. The 
majority of non-viral vector formulations on record are based on cationic lipids [19,20], 
polymers [21], nanoparticles [22], and polysaccharides [12,23]. More recently, gene 
delivery systems based on 3D molecular frameworks with precisely defined chemical 
structures, sizes, shape symmetry and functional group distributions have been 
developed [24-26]. Their intrinsic monodisperse character allows conducting systematic 
studies on the influence of vector modifications on the supramolecular interactions with 
nucleic acids and the consequences in transfection efficiencies [1].  
Within the context of molecular gene vectors, facially differentiated (“Janus”) 
macrocyclic entities [24,26,27], among which cyclodextrin (CD)-based derivatives are 
paradigmatic examples, have conquered a prominent position [28,29]. CDs are 
biocompatible cyclic oligosaccharides consisting of α-1,4-linked glucopyranose units 
that define a cone-shape topology with well-differentiated faces. The Janus feature can 
be imparted by bidirectional functionalization with polycationic groups on one rim and 
hydrophobic chains on the opposite rim. Multihead-multitail polycationic amphiphilic 
CDs (paCDs) with self-assembling properties and biomimetic cell-membrane-crossing 
aptitudes, resembling both cationic lipids and cationic polymers, are thus accessed 
[30,31]. In the presence of nucleic acids, they spontaneously form well-defined 
supramolecular nanocomplexes (hereinafter referred to as CDplexes) where the gene 
material is protected from degradation by enzymatic agents. Analogously to the well-
known lipoplexes and polyplexes [32], CDplexes can elicit cellular uptake in 
physiological media and promote transfection [30,31,33,34]. 
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Whereas in vitro transfection of immortalized cultured cells can be generally 
conducted in serum-free medium, some ex-vivo and any in vivo GT protocol will imply 
exposing of the nucleic acid-entrapping nanosystems to other biomolecules present in 
biological fluids. Non-specific interactions with these biomolecules may then decisively 
affect their fate in a biological environment [35,36]. Indeed, once administered in vivo, 
the nanovectors are exposed to the biological fluids from which they adsorb proteins 
and other components, losing the bare vector identity to form a biologically active 
corona, known as the protein corona (PC) [37,38]. This PC plays an important role in 
both the cellular recognition [39] and cell-membrane crossing capabilities 
(internalization process) of the nanovector [40]. It has also a clear effect on its time of 
circulation in the blood, so that knowing the proteomic profile of the corona 
surrounding a gene vector is crucial to optimize the transfection process. For instance, 
certain proteins like opsonins and, specially, immunoglobulins, fibrinogen and 
complement proteins are recognized by the macrophages favoring the phagocytosis and 
the rapid clearance of the vector from the bloodstream. On the other hand, the 
adsorption of apolipoproteins and serum albumin (dyopsonins) promote prolonged 
blood circulation half-life [41]. Successful delivery of therapeutic genes into cells will 
therefore require not only a high control of the physical-chemical parameters of the 
vector and vector-DNA nanocomplex, such as effective charges, chemical composition, 
size and structure, but also a deep knowledge on their interaction with serum proteins, 
the composition of the resulting PC and its impact in transfection capabilities and 
toxicity. Notwithstanding, up to date, most studies in this field are centered on the PC 
that forms around inorganic and organic nanoparticles [40,42-44], with only a few 
investigations evaluating the PC adsorbed on vector-DNA complexes [45,46]. 
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This work is specifically focused on the biophysical and biochemical 
characterization of Janus paCD-pDNA CDplexes and their protein corona fingerprints 
as a function of the molecular paCD vector topology. We have chosen three different 
paCD representatives with a -cyclodextrin (CD) core, namely compounds ADM70, 
ADM105 and PBO234 (Scheme 1). The three molecular vectors share a C7-
symmetrical skirt-type Janus architecture with a multitail lipophilic domain formed by 
fourteen hexanoyl groups that esterify the secondary hydroxyls, differing in the 
architecture of the multivalent cationic cluster installed at the primary positions. Thus, 
ADM70 displays a dendritic presentation of fourteen primary amino groups, ADM105 
a linear arrangement of seven secondary and seven primary amino groups and PBO234 
a heptavalent cluster of primary amino groups. ADM70 and ADM105 additionally 
incorporate a belt of seven thiourea groups at the primary face branches. All these 
structural elements have been previously found to impart good DNA compaction 
abilities to molecular gene vectors as well as good transfection capabilities to the 
corresponding vector-DNA complexes in cellulo and in vivo [33,34]. We have first 
conducted a deep electrochemical and structural characterization of the bare nanovector 
and pDNA-loaded Janus paCD assemblies by using high precision experimental 
techniques including zeta potential, agarose gel electrophoresis, dynamic light scattering 
(DLS), small angle X-ray scattering (SAXS) and cryo-transmission electron microscopy 
(cryo-TEM). Given that what cells “see” and process in in vivo situation is not the bare 
complexes but the CDplexes-PC bioentity formed, we have evaluated the PC developed 
at the surface of CDplexes formulated with the three paCDs herein used when they 
interact with human plasma (HP), by means of nano liquid chromatography tandem 
mass spectrometry (nanoLC-MS/MS). Finally, transfection performances of the 
CDplexes and levels of cellular toxicity were further investigated in vitro by 
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fluorescence-activated cell sorting (FACS) and reduction of 3-(4,5-dymethylthiazol-2-
y1)-2,5-diphenyl tetrazolium bromide (MTT assay), respectively.  The final goal of this 
pluridisciplinary approach is obtaining a global picture of the optimal requirements for 
the preparation of the CDplexes, in an attempt of opening alternative trails that provide 
non-viral vectors with improved outputs of bioavailability and transfection efficiency 
(TE). 
 
 
 
 
 
 
 
 
 
Scheme 1. Structural characteristics of ADM70, ADM105 and PBO234. 
 
2. Experimental section 
2.1 Materials  
The Janus paCDs used in this study, ADM70, ADM105 and PBO234 (Scheme 1), 
were prepared following the procedures previously reported [47]. Briefly, the synthesis 
of compound PBO234 was accomplished in four steps (i-iv) from commercially 
available -cyclodextrin by (i) heptabromination at the primary hydroxyl rim with the 
N-bromosuccinimide (NBS)/triphenylphosphine (TPP) system [48],
 
(ii) cesium 
carbonate promoted nucleophilic displacement of bromine by N-Boc-cysteamine [49], 
=
= = =
=
+
ADM70
ADM105
PBO234
ADM70 ADM105 PBO234
+
CD paCD
8 
 
(iii) acylation of the fourteen secondary hydroxyls by reaction with hexanoic anhydride 
in N,N-dimethylformamide (DMF) and N,N-dimethylaminopyridine (DMAP) as a non-
nucleophilic base catalyst and (iv) final acid-promoted hydrolysis of the tert-butyl 
carbamate groups. Compounds ADM105 and ADM70 were obtained from PBO234 
after isothiocyanation of the seven amino groups with thiophosgene [47] followed by 
thiourea coupling reactions with mono-N-Boc-ethylenediamine or N,N”-di-Boc-
ethylenetriamine, respectively, and subsequent Boc removal. The physicochemical data 
for the three polycationic amphiphilic cyclodextrins were consistent with those 
previously reported [47]. Most significantly, the 
1
H and 
13
C NMR spectra showed the 
typical single-spin system for fully C7-symmetrical molecules. 
pEGFP-C3 Plasmid DNA (pDNA) was extracted from competent E. Coli bacteria 
previously transformed with pEGFP-C3, the extraction being carried out using 
GenElute HP Select plasmid Gigaprep Kit (Sigma Aldrich) following a protocol 
previously described [50,51]. Sodium salt of calf thymus DNA (ctDNA), provided by 
Sigma-Aldrich, was used as linear DNA to determine the effective charge ( ) of the 
cationic vector. 
Human plasma (HP) whole blood provided by the Department of Experimental 
Medicine of La Sapienza University of Rome, was obtained by venipuncture of ten 
healthy volunteers. Mixed plasma was aliquoted and stored at -80 ºC in protein LoBind 
tubes until further use. For analysis, the aliquots were thawed at 4 ºC and then allowed 
to warm at room temperature. Human cervical cancer cell line (HeLa), derived from 
human cervix adenocarcinoma, and human breast cancer cell line (MCF-7), derived 
from human pleural effusion breast cancer metastasis, were purchase from ATCC 
(Manassas, VA, USA). HeLa cells were maintained in Eagle’s Minimum Essential 
Medium (EMEM) supplemented with 2 mM L-glutamine, 100 IU/mL 
+
CD
q
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penicillin/streptomycin, 1 mM sodium pyruvate, 10 mM HEPES, 1.5 mg/L sodium 
bicarbonate, and 10% fetal bovine serum (FBS). MCF-7 cells were maintained in 
Eagle’s Minimum Essential Medium (EMEM) supplemented with 0.01 mg/ml human 
recombinant insulin and 10% fetal bovine serum (FBS). 
 
2.2 Methods 
 2.2.1 Preparation of CDplexes. paCD-DNA complexes were formed by mixing the 
correct amounts of aqueous solutions of the paCDs and of DNAs (either ctDNA or 
pDNA) in HEPES 20 mM (pH = 7.4). The final solutions were left during 20 min prior 
to carry on the experiments. pDNA concentrations were optimized to fit the optimum 
conditions for each experimental technique. CDplex composition can be expressed 
either in terms of the masses ratio  CD DNAm / m  , between mass of the gene vector (
) to plasmid DNA  DNAm , or the effective charge ratio (ρeff), between the paCD 
and pDNA effective charges.  
2.2.2. Incubation of paCDs with HP, in absence and presence of pDNA. paCDs 
were mixed with HP (1:1 v/v) and were incubated at 37 ºC for 1 h. After incubation, the 
samples were centrifuged three times during 15 min at 14000 rpm in order to wash the 
sample and remove all the molecules not bound to the complex. The same procedure 
was followed with the CDplexes.  
2.2.3. Methods for the characterization of paCD/pDNA CDplexes. Uncomplexed 
plasmid DNA along with the paCD/pDNA CDplexes (at several  CD pDNAm / m ratios) 
were loaded onto 1% agarose gel and run for 30 min at 100 mV in 1x TAE (Tris-HCl, 
Acetate and EDTA) buffer. In the Agarose gel electrophoresis experiments, fully 
paCD/pDNA complexes appeared as fluorescent band in the wells of the gel, while 
CD
m
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uncomplexed pDNA appeared outside the well. Fluorescence intensity of each band was 
measured by using commercial Quantity One software provided with Gel Doc XR 
instrument (Bio-Rad). The band intensity for the free pDNA was considered as 100% 
and other intensities were estimated accordingly. 
ζ-potential measurements (obtained from electrophoretic mobility) for bare CDplexes 
were carried out at 25 ºC, with a Phase Analysis Light Scattering technique (Zeta PALS, 
Brookhaven Instrum. Corp., USA) [52,53]. ζ-Potential was measured at different 
 CD DNAm / m ratios of the CDplexes. Each electrophoretic mobility datum is taken as an 
average over 50 independent measurements. Size and ζ-potential measurements for PC-
coated CDplexes (in the presence of HP) were carried out using a Zetasizer Nano ZS90 
(Malvern, UK). CDplex-HP samples (1:1 volume ratio) were previously incubated for 
1h at 37 ºC. CDplex-protein complexes were separated from excess plasma by 
centrifugation and extensive washing to remove the unbound proteins. For all of the 
samples investigated, the data show mostly a unimodal distribution and represent the 
average of at least five different measurements carried out for each sample. Results are 
given as means ± standard deviation of the five replicates. 
Small-angle X-ray scattering (SAXS) experiments were carried out on the beamline 
NCD11 at ALBA Synchrotron Barcelona (Spain). The energy of the incident beam was 
12.6 KeV ( = 0.995 Å). The machine is run in multibunch mode with a filling pattern 
consisting on 10 trains, 64 ns long and a gap of 24 ns between the trains. Samples were 
placed in sealed glass capillaries purchased from Hilgenberg with an outside diameter of 
1.5 mm and wall thickness of 0.01 mm. The scattered X-ray was detected on CCD 
detector Quantum 210r, converted to one-dimensional scattering by radial averaging, 
and represented as a function of the momentum transfer vector. SAXS experiments 
were run, at several effective charge ratios (eff) of the CDplexes.  
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Cryo-transmission electron microscopy (Cryo-TEM) experiments were run for 
paCD/pDNA CDplexes following the standard procedure [54,55]. In these experiments, 
perforated Quantifoil R1.2/1.3 (hole diameter 1.2 µm) on a 400-mesh copper grid were 
used. Images were obtained using a Jeol JEM 2011 cryo-electron microscope operated 
at 200 kV, under low-dose conditions, and using different degrees of defocus (500–700 
nm) to obtain an adequate phase contrast [56]. Images were recorded on a Gatan 794 
Multiscan digital camera. Finally, the CCD images were processed and analyzed with a 
Digital Micrograph.  
In order to carry on nanoLC-MS/MS analysis, 10 L peptide mixtures were 
separated by RP chromatography using the Dionex Ultimate 3000 (Dionex Corporation 
Sunnyvale, CA, USA). Samples were on-line preconcentrated on a -precolumn 
(Dionex, 300 mi d. × 5 mm Acclaim PepMap 100 C18, 5 m particle size, 100 Å pore 
size), employing a premixed mobile phase doubled distilled (dd) H2O:ACN 98:2 (v/v) 
containing 0.1% (v/v) TFA at a flow-rate of 10 L min−1. Samples were then separated 
on an in-house manufactured Acclaim-C18 2.2 m silica microparticles (75 mi d. × 25 
cm) and outlet Kasil frit. A multi-step gradient was employed for sample 
chromatography, using ddH2O:ACN (98:2, v/v) with 0.1% TFA as phase A and 
ACN/TFA (99.9/0.1, v/v) as phase B. Starting from 1% phase B, such composition was 
maintained for 5 min, then phase B was linearly increased to 5% within 2 min; 
afterwards, phase B was first increased to 20% within 100 min and then to 50% within 
43 min; then to 80% within the following 5 min. Phase B was maintained at 80% for 20 
min to rinse the column and finally lowered to 1% within 1 min. The column was then 
equilibrated at this percentage for 43 min. The flow rate was 250 nL min
-1
 and the total 
run time was 120 min. The nanoHPLC apparatus was directly connected with an 
Orbitrap Elite hybrid ion trap-Orbitrap mass spectrometer (Thermo Scientific, Bremen, 
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Germany) by a nano-electrospray ion source for MS/MS analysis of eluting peptides. 
Orbitrap Elite was operated to collect spectra over them/z range of 400–1800 Da, at 
60,000 (Full Width Half Maximum at m/z 400) resolution, in the data dependent mode. 
MS/MS spectra were collected in top 20 mode, rejecting +1 and unassigned charge 
states, using a normalized collision energy of 35%, and an isolation window of 2 m/z. 
Ion trap and Orbitrap maximum ion injection times were set to 100 and 200 ms, 
respectively. Automatic gain control was used to prevent overfilling of the ion traps and 
was set to 1 × 106 for full FTMS scan, and 1 × 104 ions in MSn mode for the linear ion 
trap. To minimize redundant spectral acquisitions, dynamic exclusion was enabled with 
a repeat count of 1 and a repeat duration of 30 s with exclusion duration of 70 s. For 
each sample, three technical replicates (LC-MS/MS runs) were performed. 
For data analysis and protein validation procedures, raw data files, obtained from 
Xcalibur software, were submitted to Proteome Discoverer (1.2 version, Thermo 
Scientific) for database search using Mascot (version 2.3.2 Matrix Science). Data were 
searched against human entries in the SwissProt protein database (57.15 version, 20266 
sequences) selecting the built-in decoy option. Trypsin was specified as the proteolytic 
enzyme with up to two missed cleavages. Carbamidomethylation of cysteine and 
oxidation of methionine were set as fixed and variable modification, respectively. The 
monoisotopic mass tolerance for precursor ions and fragmentation ions were set to 10 
ppm and 0.8 Da, respectively. To validate protein identifications derived from MS/MS 
sequencing results, the Mascot output files (.dat) were submitted in the commercial 
software Scaffold (v3.1.2, Proteome Software, Portland, Oregon, USA; 
http://www.proteomesoftware.com/). The scaffold tool to integrate Mascot 
identification results with X!Tandem search engine results (performed in automatic with 
the same parameters settled for Mascot) was used. Only protein identification based on 
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mass spectra correlating to at least two unique tryptic peptides were considered; 
minimum peptide identification probability was set at 95%, whereas protein 
identification probability was set at 99%. For protein quantitative analysis, Scaffold 
software allows the normalization of the spectral countings (normalized spectral 
countings, NSCs) and offers various statistical tests to identify significant abundance 
differences in two or more categories. The mean value of NSCs obtained in the three 
experimental replicates for each protein was further normalized to the protein molecular 
weight (MWNSC) and expressed as the relative protein quantity by applying Eq. (1): 
1
100



N
i
( NSC / MW )
MWNSC
( NSC / MW )
                                                     (1) 
where MWNSCk is the percentage molecular weight normalized NSC for protein k, and 
MW is the molecular weight in kDa for protein k. This correction takes into account the 
protein size and evaluates the actual contribution of each protein reflecting its relative 
protein abundance (RPA) in the “hard corona”. 
On transfection efficiency analysis, HeLa and MCF-7 cells were seeded in 12-well 
plate (150x10
3
 cells/mL) and treated with paCD/GFP plasmid complexes alone or 
surrounded by protein corona for 48 h. Then, cells were detached with trypsin/EDTA, 
washed two times with cold PBS and acquired using a flow cytometer. Fluorescence-
activated cell sorting (FACS) analysis was performed using BD LSRFortessa equipped 
with 488 nm laser and with DIVA software (BD Biosciences, San Jose, CA, USA). 
Cells were first gated using forward vs side scatter (FSC vs SSC) strategy to exclude 
debris (low events) and then analyzed for the specific 530 nm emission (FITC channel). 
Data were analyzed using FlowJo software (FlowJo LLC data analysis software, 
Ashland, OR, USA). Transfection efficiencies (TE) were quantified by means of % GFP 
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cells, i.e., percentage of cells in which GFP expression is observed, and the average 
intensity of fluorescence per cell (MFI). Lipofectamine was used as a positive control. 
Cell viability of HeLa and MCF-7 cell lines was assessed by 3-(4,5-dymethylthiazol-
2-y1)-2,5-diphenyl tetrazolium bromide (MTT, mitochondrial respiration analysis; 
Sigma-Aldrich), according to Mosmann protocol. Briefly, HeLa and MCF-7 cells were 
seeded on 96-wells plate and, after 24 h, treated with the three paCDs (ADM70, 
ADM105 and PBO234) complexed with pEGFP-C3 plasmid alone or surrounded by 
protein corona for 24 h. MTT was added to each well at the final concentration of 0.5 
mg/mL and after 4 h of incubation at 37 ºC, the formazan salt was dissolved with 100 
mL isopropanol. The absorbance of each well was measured with Glomax Discovery 
System (Promega) at 550 nm wavelength and the viability was calculated for each 
treatment as “OD of treated cells/OD of control cells” x100.  
 
3. Results and discussion 
Nanocomplex formation between non-viral gene vectors and nucleic acids is 
primarily driven by coulombic interactions. A proper characterization requires thus 
determination of the charges available in each partner, which are usually different from 
the nominal ones defined by the number of potentially ionizable groups. Regarding the 
oligonucleotide counterpart, studies reported in the literature [3,12,51,53] have shown 
that linear DNAs, such as commercial calf thymus or salmon sperm DNA, or short 
siRNAs have their negative charge totally available for the gene vector, i.e. 
linearDNA
q

= -2 
per bp. In stark contrast, experiments recently reported [19,20,53] have demonstrated 
that, at physiological conditions, plasmid DNAs remain in a supercoiled conformation, 
rendering a much less negative charge than its nominal one (
pDNA
q

<< -2).  
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For that reason, the characterization of the CDplexes must start with the 
determination of the effective charges of both the policationic Janus paCD and the 
pDNA, when forming the nanocomplex. At this respect, we have implemented a 
procedure to fulfil this objective based on a two-step protocol to determine: i) firstly, 
the effective charge of the cationic vector by characterizing the complex formed by this 
vector and double stranded linear DNA (linear DNA) for which the charge is well 
established (-2/bp); and ii) on a second step, the effective charge of the pDNA by 
characterizing the complex formed by the cationic vector, already of known charge 
(step i), and the pDNA in the same experimental conditions [51-53]. Briefly, the 
effective charge ratio ( ), defined as the quotient between the effective charges of 
the paCD amino groups and the DNA phosphate groups is given by the following 
equation: 
   (2)
 
where n
+
 and n
-
 are the number of moles of positive and negative charges of paCD and 
DNA; and are the masses of the cationic CD based vector and the nucleic 
acid; and  are the molar mass of the vector and the average molar mass of 
DNA per bp; and and are the effective charges of paCD and DNA per bp, 
respectively. When n
+
 balances n
-
, equals 1 and the electroneutrality of the complex 
is reached. The particular  CD DNAm / m  ratio at which this charge compensation occurs, 
defined hereinafter as  CD DNAm / m  , marks the lower limit from which the CDplex 
becomes a potentially efficient cell transfecting agent, since it turns to a net positively 
eff

,
,
( / )
( / )
eff CD CD CD
eff
bpeff DNA DNA
q m Mn
n q m M





 
CD
m
DNA
m
CD
M bpM
,eff CD
q

,eff DNA
q

eff

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charged complex, as required to cross the negative cell membrane in an efficient cell 
transfection process. From Eq. (2), it is easily deduced that = 1 requires: 
 (3) 
Thus, if the isoneutrality ratio  CD linearDNAm / m   is experimentally determined for a 
complex formed by a Janus CD-based vector and a commercial linear DNA (for which 
= -2/bp), the effective positive charge of the vector ( ) can be obtained. 
Once this charge is known, the negative effective charge of the plasmid ( ) can 
be straightforwardly determined from the experimental value of  CD pDNAm / m   for a 
complex formed by the same CD based vector but with a plasmid DNA instead of the 
linear DNA, on the same experimental conditions, as follows: 
   (4)
 
Electrochemical techniques are, among others, the most adequate tools to determine 
this electroneutrality ratio, agarose gel electrophoresis, and, more precisely, zeta 
potential, being the most recommended. Agarose gel electrophoresis informs about the 
compaction level of pDNA by the vectors. Fig.1 reports these experiments at three 
different  CD DNAm / m  ratios (white numbers on lanes 2-4), for the three paCDs used in 
this work (ADM70, ADM105 and PBO234). Uncomplexed pDNA (lane 1) was used 
as a positive control. Results reported in Fig. 1 reveal that pDNA is efficiently 
compacted by the paCD molecular vectors, since the fluorescent bands disappear across 
the gel lanes as long as  CD DNAm / m ratio increases. As can be inferred from Fig. 1, the 
eff

1
, ,linear
CD CD
eff CD eff DNA
bplinearDNA
m M
q q
m M


     
 
,lineareff DNA
q

,eff CD
q

,peff DNA
q

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pDNA CD
m M
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isoneutrality was reach at  CD DNAm / m ratios below 0.4, 0.7 and 0.5 for ADM70-
pDNA, ADM105-pDNA and PBO234-pDNA CDplexes, respectively.  
With the aim of determining with higher precision the electroneutrality ratio, zeta 
potential was measured as a function of  CD DNAm / m  (Fig. 2), covering the range 
within which pDNA is effectively compacted by each paCD, according to the results 
shown in Fig. 1. The electroneutrality ratio  CD DNAm / m   can be determined as the  
 CD DNAm / m value where a sign inversion on the charge occurs in the -potential 
sigmoidal profiles.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Gel electrophoresis results for (a) ADM70-pDNA CDplexes, (b) 
ADM105-pDNA CDplexes, and (c) PBO234-pDNA CDplexes. Lane 1: 
uncomplexed pDNA (positive control). Lanes 2-4: CDplexes at different 
mCD/mDNA mass ratios (white numbers at the bottom of the lanes). 
pDNA          mCD/mDNA  
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Fig. 2. Plot of ζ potential vs mCD/mDNA CDplex composition, for different samples with 
ctDNA (a) and pDNA (b). Black, red and blue symbols correspond to ADM70-pDNA, 
ADM105-pDNA and PBO234-pDNA CDplexes, respectively. 
 
Table 1 reports the results obtained for CDplexes formulated with ADM70, 
ADM105 or PBO234 and either ctDNA or pDNA. With these  CD DNAm / m  values 
and following the procedure above explained, the effective charges of both the Janus 
CD based cationic vectors and the pDNA herein used,  and , were 
calculated and collected in Table 2. The differences encountered between nominal and 
effective charges in both the cationic vectors and the anionic pDNA are remarkable. 
Thus, the net positive charges available for interaction with pDNA are around 33% of 
the nominal one, assuming full protonation of the amino groups, for the tetradecaamine 
derivatives ADM70 and ADM105, and only 25% for heptamine PBO234. This 
scenario is similar to that found for some CD polyrotaxane-based vectors [12] but 
sharply different from that encountered for cationic lipid gene vectors bearing 
quaternary amino groups, which normally yield their total nominal positive charges 
within a range of 10 % of uncertainty [19,51,57]. On the other hand, the plasmid used 
herein seems to be quite supercoiled at the experimental conditions used, since its 
available negative charge per bp is far away from the nominal value (-2/bp), yielding 
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around 7%, 13% and 5% of its nominal charge when being compacted by ADM70, 
ADM105 and PBO234, respectively. This behaviour, often found in lipoplexes, 
confirms that plasmids usually retain an important percentage of cationic sodium 
counter-ions (Na
+
). This is a priori a favourable feature for the use of these macrocyclic 
vectors as safer and effective vehicles of nucleic acids, since the weaker the anionic 
character of the DNA, the lower the amount of cationic vector needed to formulate the 
nanocomplexes, thus decreasing the risk of cytotoxicity of the vector. From the paCD 
and pDNA effective charges thus obtained, effective charge ratios (eff) around 5-fold 
(for ADM70 and PBO234) or 2- to 3-fold (for ADM105) of the nominal ones were 
calculated using Eq. (2). 
Table 1. Values of isoneutrality ratios  CD DNAm / m  for the CDplexes formed by 
ADM70, ADM105 and PBO234 with either ctDNA or pDNA. 
 ADM70-DNA ADM105-DNA PBO234-DNA 
ctDNA 3.0 2.9 5.7 
pDNA 0.19 0.38 0.25 
Values estimated with a 5% error 
Table 2. Nominal and effective charges of paCDs and pDNA.  
 ADM70 ADM105 PBO234 
nom,CD
q
  14 14 7 
eff,CD
q

 4.6 4.7 1.7 
eff,CD nom,CD
q / q
 
 0.33 0.33 0.25 
nom,pDNA
q / bp

 -2 -2 -2 
eff,pDNA
q / bp

 -0.13 -0.26 -0.09 
eff,pDNA nom,pDNA
q / q
 
 0.07 0.13 0.05 
eff/nom 5.1 2.6 5.4 
Values estimated with an 8% error 
 
Having information of the structure of the complex is important to find the best non-
viral vectors and to promote its use in in vivo gene therapy. The structure of the paCD-
pDNA CDplexes in concentrated samples was investigated by SAXS at several 
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effective charge ratios for which CDplexes are potentially active as gene transfection 
vectors (eff > 1). Cryo-TEM was also used as a supporting technique. Fig. 3 shows the 
corresponding SAXS diffractograms (Intensity vs q factor) at eff = 2, 4 and 8, with the 
Miller indexes being included in the plot. In all the cases, three peaks that index well to 
a lamellar lyotropic liquid crystal phase (L) were observed, regardless of eff, with the 
characteristic inter-layer distance (d) directly related to the q factor (d = 2πn/q
hkl
, n is 
the diffraction order). This structure may be explained by considering that the hexanoyl 
chains linked to the wider entrance of the CD torus promote self-assembling in a 
lipidic bilayer fashion, CDplexes being adequately represented as alternating bilayers of 
paCDs molecules and an aqueous monolayer containing supercoiled pDNA, with 
thicknesses represented by dm, and dw, respectively, being d = dm + dw. 
Table 3 collects the values of d, calculated as an average of the data obtained from 
the more intense peaks (100 and 200) of the diffractograms at each eff ratio. It is 
noticeable that the periodicity of the structure remains basically unaltered for a constant 
pDNA content when the proportion of the vector increases (i.e. d remains basically 
constant with eff), for the three CDplexes studied. Considering these d values and the 
fact that pDNA supercoils needs around dw ~2.0-2.5 nm to be sandwiched by paCDs 
bilayers in a typical sandwich fashion, it can be deduced that the thickness of the 
bilayer (dm) must be 3.1, 3.4 and 2.5 nm for ADM70-pDNA, ADM105-pDNA and 
PBO234-pDNA CDplexes, respectively. Given the lengths of both the cationic tails and 
the lipid type chains, and the depth of the -CD torus-shaped cavity, these d, dm and dw 
values are compatible with a L structure only if: i) the cationic tails on the narrower 
entrance of the CD macrocycle are somehow in an open bouquet fashion (to avoid 
electrostatic repulsions among positive charges) and/or ii) the lipidic type chains that 
are linked to the wider entrance of -CD macrocycle are intercrossed.  
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Fig. 3. SAXS diffractograms of paCD-pDNA CDplexes at several effective 
charge ratios (ρeff): Red lines ρeff = 2, green lines ρeff = 4, and blue lines ρeff = 8 
for: a) ADM70-pDNA; b) ADM105-pDNA; and c) PBO234-pDNA CDplexes. 
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Table 3. Values of q and d of the lamellar (L) liquid crystal phase found for the paCD-
pDNA CDplexes (where paCDs are ADM70, ADM105 and PBO234), at several 
effective charge ratios (eff).  
  ADM70 ADM105 PBO234 
eff  L L L 
 q100 1.12 1.06 1.28 
2 q200 2.21 2.09 2.50 
 q300 3.30 3.12 - 
 d 5.6 5.9 5.0 
 q100 1.13 1.09 1.31 
4 q200 2.23 2.13 2.47 
 q300 3.33 3.16 - 
 d 5.6 5.8 5.0 
 q100 1.15 1.07 1.30 
8 q200 2.27 2.12 2.50 
 q300 3.39 3.18 - 
 d 5.5 5.9 4.9 
Values of q and d are reported in nm
-1
 and nm, respectively. 
 
Cryo-TEM experiments further confirmed the multilamellar character of the 
CDplexes studied in this work. Fig. 4 shows a selection of micrographs among those 
taken for ADM105-pDNA CDplex that are representative of the ensemble of data (see 
Fig. S1 in Supplementary data for a selection of micrographs of ADM70-pDNA and 
PBO234-pDNA CDplexes). The multilamellar arrangement found in SAXS is also seen 
in these micrographs. In fact, three types of nanostructures in coexistence are found: (i) 
CDplexes with a well-defined multilamellar profile and aggregated in a cluster type 
fashion (CT-type nanoaggregates; labelled with white asterisks in Fig. 4); (ii) CDplexes 
with a clear finger-print multilamellar pattern (FP-type nanoaggregates; labelled with 
white circles, and a zoom view in panel d), and; (iii) self-aggregated paCDs without 
pDNA compacted (labelled with white arrows), with a typical vesicle-type structure. 
The presence of aggregates of paCD molecules, without pDNA being compacted, is 
justified by the fact that the experiment is done for samples with a clear excess of 
cationic vector (notice that eff = 4 in cryo-TEM experiments). These exceeding paCD 
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molecules tend to form unilamellar spherical vesicle-type nanostructures, the formation 
of the lipidic bilayer being promoted by the presence of 14 lipidic type chains linked to 
the wider entrance of each cyclodextrin torus (2 chains per glucose unit). It can be 
inferred that the unilamellar paCD vesicles above mentioned interact with pDNA 
through strong electrostatic interactions and tend to aggregate yielding the 
multilamellar phases, either CT or FP, by sandwiching the plasmid supercoils within 
the aqueous monolayer that remain between each two bilayers. Scheme 2 shows 
schematic drawings of both nanoaggregates: (a) unilamellar vesicles in the absence of 
pDNA, and (b) multilamellar complexes in the presence of pDNA. In the CT-type 
structures, the bilayers may be deformed when sandwiching pDNA supercoils with the 
adjacent bilayers, but they essentially keep their morphologies. However, FP-type 
nanoaggregates show the typical finger-print compaction pattern, and in contrast with 
the CT-type CDplexes, the bilayers tend to disrupt probably due to a more favourable 
paCD-pDNA interaction. This particular scenario has been also previously found for 
different lipoplexes (cationic lipids-pDNA complexes) [20,57]. Some of the 
multilamellar arrangements shown in these micrographs (and other not shown) have 
been chosen to analyze the presence of periodicity. As representative examples, the 
insets of panels b) and c) in Fig. 4, show Fast Fourier Transform (FFT) profiles where 
the diffraction spot corresponds to a typical lamellar pattern.  
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Fig. 4. A selection of cryo-TEM micrographs showing a general view of the ADM105-
pDNA CDplexes at eff = 4. Insets on panels b) and c) show the diffraction spots from 
FFT calculations over a selected area on the original micrograph (yellow square). FFT 
pattern reveals a multilamellar structure. Scale bars are 100 nm in panels a-c and 50 nm 
in panel d. 
 
 
 
 
 
 
 
 
 
 
Scheme 2. Schematic drawings of: a) Vesicles-type paCD self-aggregation pattern; and 
b) Multilamellar lyotropic liquid crystal phase (L) of the CDplexes studied in this 
work, showing the structural parameters, d, dm and dw. 
a) b) 
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Accordingly, the ensemble of electrochemical and structural results shows L self-
assembling patterns irrespectively of eff values, while the best compaction levels are 
obtained at eff  = 4. Additionally, it is known that CDplexes must be positively charged 
(eff > 1), but with cationic vector content being as low as possible to diminish 
cytotoxicity. All these considerations point to eff = 4 as a potentially adequate charge 
ratio to carry on both the proteomic and TE studies.  
Upon in contact with biological milieu, CDplexes will adsorb plasma proteins in a 
time-dependent manner. Most abundant proteins will bind to vector surface first and 
will be progressively substituted by proteins with high affinity for the surface of 
CDplexes. At the equilibrium (typically reached within 1 h exposure), the PC of 
CDplexes will be constituted by a longstanding protein layer referred to as the hard 
corona (HC), which will provide CDplexes with their biological identity, plus a soft 
corona (SC) made of proteins in dynamical exchange with the surrounding 
environment. In the present investigation, both paCDs and CDplexes were let to interact 
with HP for 1 h. The PC formation was confirmed by means of -potential and size 
measurements of the CDplexes in the absence and in the presence of HP. The data 
collected in Table 4 indicate that the bare complexes are positively charged (-potential 
around +30 mV), with mean hydrodynamic diameters of around 114 nm in the case of 
ADM70-pDNA CDplexes and around 150 nm for the other two CDplexes. After 1 h 
incubation with HP, a clear increase on the size of the complexes (hydrodynamic 
diameter increases around 40-45 nm in the three cases), and a marked drop in -
potential, shifting from positive to negative (from ca. +30 mV to ca. −17 mV), were 
observed. These evidences are clearly compatible with the formation of a ca. 20-nm-
thick PC, mostly consisting of negatively charged proteins (i.e. pI < 7), that are located 
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at the CDplex surface. It is also remarkable that ADM70-pDNA formulations, either in 
the absence or in the presence of HP, exhibited higher stability and homogeneity in size 
(in view of PdI values) as compared to ADM105 and PBO234 formulations. 
Table 4. Hydrodynamic diameter (Dh), polydispersity index (PdI) and -potential values 
of ADM70-pDNA, ADM105-pDNA and PBO234-pDNA CDplexes formulated at eff = 
4 before and after exposure to HP for 1h. 
 Dh (nm) PdI -potential (mV) 
ADM70-pDNA 114 ± 6 0.21 ± 0.01 29.8 ± 1.2 
ADM70-pDNA + HP 153 ± 8 0.34 ± 0.03 -17.4 ± 2.5 
ADM105-pDNA 149 ± 15 0.41 ± 0.08 31.7 ± 2.2 
ADM105-pDNA+HP 191 ± 18 0.64 ± 0.13 -16.3 ± 2.5 
PBO234-pDNA 155 ± 12 0.53 ± 0.09 28.4 ± 1.4 
PBO234-pDNA+ HP 203 ± 28 0.66 ± 0.16 -18 ± 7 
 
NanoLC-MS/MS experiments were run with the aim of identifying the corona 
proteins of the Janus paCD-pDNA formulations herein studied upon incubation with 
HP. In the case of PBO234 and PBO234-pDNA CDplexes, incubation with HP did 
produce a tightly bound PC that could not be solubilized within the concentration range 
according to the standard protocols, preventing any further analysis. For ADM70 and 
ADM105 formulations, the relative protein abundance (RPA) of all the identified 
corona proteins was determined. Tables S1 and S2  report the top 25 most abundant 
proteins found within the corona of ADM70 and ADM105, respectively (in the absence 
and presence of pDNA). All the proteins constituting the corona and these top 25 most 
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abundant ones are classified by their molecular mass (MW) and their isoelectrical point 
(pI) in Fig. 5. In the absence of pDNA, ADM70 PC is formed mostly by proteins with 
molecular weight between 60-80 kDa (RPA~23%) and 150-300 kDa (RPA~11%). In 
the PC of ADM70-pDNA CDplex, proteins between 60-80 kDa remains roughly the 
same (RPA~21%), while a slight decrease in high MW proteins (150-300 kDa, RPA 
from 11 to 8%) and an increase in those under 20 kDa (RPA from 7 to 11%) was 
observed. Experiments for ADM105 show that proteins with a molecular weigh 
between 60-80 kDa have RPA~28%, irrespective of the absence or presence of pDNA, 
while the RPA for proteins with MW 150-300 kDa increases from ~8% for ADM105 to 
14% for ADM105-pDNA CDplexes. For both cyclodextrin-based vectors, with and 
without pDNA, the corona is made up of proteins with a pI between 5 and 6 (33% for 
ADM70 and 44% for ADM105), meaning that the adsorbed proteins have mostly a 
negative charge (pI < 7), in total agreement with the zeta potential results above 
commented. These results are in concordance with the idea that electrostatic 
intermolecular forces drive the non-covalent interaction between proteins and the 
cationic vectors.   
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Fig. 5. Percentage of total proteins of corona proteins of ADM70 and ADM105 in the 
absence and presence of pDNA, classified according to their calculated molecular mass, 
MW (a), and isoelectric point, pI (b). Percentage of total proteins of the top 25 corona 
proteins classified according to their calculated molecular mass, MW (c) and isoelectric 
point, pI (d). Percentage of total proteins was calculated as explained in the 
experimental section. 
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Fig. 6. Percentage of the proteins found within the protein corona (PC) of ADM70 and 
ADM105, in the absence and presence of pDNA, classified by their physiological 
functions. 
 
Corona proteins are also classified by their physiological functions (Fig. 6). For 
ADM70 and ADM105 nanoaggregates and for the corresponding CDplexes, 
complement, lipoprotein and coagulation were found to be the most abundant proteins, 
whereas immunoglobulins, tissue leakage and acute phase proteins constituted a minor 
fraction of the PC. Complement proteins promote elimination from systemic circulation, 
accumulation in the liver, spleen and clearance, and they are involved in immune 
response. Coagulation proteins are involved in coagulation processes, whereas 
lipoproteins affect the intracellular trafficking. Figs. S2 and S3 report a bioinformatic 
classification of corona proteins, in terms of percentage of total proteins identified for 
each functional class. As can be inferred from those plots, prothrombin presents the 
highest percentage for both paCDs in the absence of pDNA, followed by C4BPA, 
vitronectin, albumin and APOA1. In the case of the CDplexes, the trend is very similar, 
although the abundance of albumin is more affected by the type of paCD and/or the 
absence/presence of pDNA. It is worthwhile mentioning that prothrombin is involved in 
ADM105 ADM105
DNA
0
20
40
60
80
100
%
 o
f 
T
o
ta
l P
ro
te
in
s
Complement  Factors
Lipoproteins
Coagulation Factors
Others
Immunoglobulins
Acute phase
Tissue leakage
ADM70 ADM70
DNA
0
20
40
60
80
100
%
 o
f 
T
o
ta
l P
ro
te
in
s
Complement  Factors
Lipoproteins
Coagulation Factors
Others
Acute phase
Immunoglobulins
Tissue leakage
30 
 
coagulation process, C4BPA controls the activation of complement classical pathway, 
vitronectin is a receptor for cancer cells, albumin promotes prolonged blood circulation 
and crossing biological barriers, while APOA1 is the major protein of high density 
lipoproteins (HDL) and can be used as a ligand.  
Lastly, transfection efficiency (TE) and cell viability of Janus paCD-based CDplexes 
have been evaluated in HeLa and MCF-7 cancer cells at eff = 4 in the absence and 
presence of Human Plasma (HP). Lipofectamine was used as a positive control. In Fig. 
7, TE results are reported in terms of % GFP expressed (panels a-b) and mean 
fluorescence intensity (MFI) (panels c-d). High values of % GFP indicate that there is a 
significant percentage of cell population expressing GFP protein, while a high MFI 
value points to a high level of GFP protein expression per cell that results from the 
number of copies of pDNA transfected, transcripted and translated per cell. Efficient 
transfection reagents often suffer, nonetheless, from high cytotoxicity. To evaluate 
whether or not Janus paCD formulations were toxic, HeLa and MCF-7 cancer cells 
were treated with the corresponding CDplexes and then subjected to MTT analysis, 
whose results are resumed in Fig. 8. Notably, Fig. 7 shows that CDplexes formulated at 
eff = 4 transfect the cells roughly as poorly efficiently as the control, in terms of MFI, 
or slightly worst, in what respect to %GFP. Nonetheless, cell viability outputs were 
reasonably good (70 - 100%) at this eff, both in absence and in presence of HP (Fig. 8).  
In an attempt to overcome such poor TE results, two strategies were designed: i) we 
increased the concentration of CDplexes/cell, but keeping eff = 4, since recent results 
[58] point to this increase as a favorable factor to improve TE performances; and/or ii) 
we increased eff, with the risk of increasing cytoxicity levels as well. Fig. S4 shows the 
results obtained working with the first approach. As can be seen, increasing the 
CDplexes concentration per cell (2X, 5X and even 10X) yield transfection efficiencies 
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even lower than those previously obtained (1X), in contrast with the standard 
Lipofectamine for which an increase in the CDplexes doses provokes a clear 
improvement on TE results for HeLa cells. Furthermore, cytoxicity levels show a slight 
increase when CDplexes/cell concentration is raised for both the samples and the 
control. This non desirable combination (decrease on TE and increase on cytotoxicity) 
clearly reveals that the first strategy must be discarded for the CDplexes herein 
reported. 
Fig. 7 shows the results obtained with the second approach, i.e. increasing eff  up to 
25 and 50, together with those corresponding to eff  = 4, previously commented. As can 
be seen, the three paCDs were more efficient transfecting pDNA than Lipofectamine 
(better %GFP and MFI values) at these higher eff,, both in the absence and in the 
presence of HP. In the absence of HP and at high eff, MFI results (Fig. 7 c-d) followed 
the trend ADM70-pDNA ≈ ADM105-pDNA > PBO234-pDNA, irrespective of the cell 
line, although the superiority of ADMs were more evident in MCF-7 cells. However, 
certain reduction in transfection efficiency promoted by the presence of HP was found, 
a feature that could be due to a reduced endosomal escape in the cytoplasm of cells. 
Indeed, while HP can promote interaction with cell receptors, fusion with endosomal 
membranes could be, at least in part, impaired by the rich protein layer adsorbed at the 
surface of the vector. Nonetheless, some proteins forming the corona could shuttle the 
complex to acid cell compartments (e.g. lysosomes) where the gene payload could be 
degraded. In spite of the reduction on TE outcomes provoked by the presence of HP, 
CDplexes consisting of ADMs, and in particular PC-coated ADM70-pDNA CDplexes, 
produced again better MFI values (primarily for MCF-7 cells), suggesting that, 
although the PC is probably detrimental for cell uptake, the intracellular steps leading 
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to protein expression, including endosome scape, trafficking to the nucleus and pDNA 
release, are particularly favorable for PC-coated ADM70-pDNA CDplexes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.7. Transfection efficiency (TE) values of paCDs-pDNA CDplexes, in terms of % 
GFP expressed (panels a-b) and mean fluorescence intensity (MFI) (panels c-d), at eff = 
4, 25 and 50, in the absence and presence of Human Plasma (HP), through HeLa and 
MCF-7 cells. CTR: cells alone. LFN: Lipofectamine, positive control.  
 
On the other hand, as shown in Fig. 8, the increase on effective charge ratio (eff) 
from 4 to 50 seems to slightly decrease the viability of HeLa cells, in the absence of HP, 
while no appreciable decrease is observed in MCF-7 cells. In the presence of PC, cell 
viability of both cell lines was not appreciably diminished. Notice, nonetheless, that 
almost all the values are around or over 80%, which is considered a minimum threshold 
value. However, interpretation of the effect of PC on the cell viability of CDplexes must 
be done with caution. Whether PC reduce cell viability or protect the cells can be due to 
specific PC composition and, in turn, to the complex relationship between PC 
composition and nanocarrier processing by cell machinery [59]. Moreover, in the 
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absence of in vivo experiments, the evaluation of PC composition, although implies an 
important improvement with respect to the use of SDS PAGE experiments alone, does 
not allow one to depict strong conclusions about future in vivo applications (i.e. 
targeting ability, bio-distribution, cytotoxicity). In fact, in the literature, major works are 
discussing about mapping protein binding sites across the PC surface. In the absence of 
this piece of information, discussion about the potential role of corona proteins should 
be made, but kept at a minimum, as done in this work. Otherwise, the risk of 
speculation may be too high.  
 
 
 
 
 
 
 
 
 
 
 
Fig. 8. Cell viability of paCDS-pDNA CDplexes at eff = 4, 25 and 50 for HeLa and 
MCF-7 cells, in the absence and presence of human plasma (HP). CTR: cells alone. 
CDS: cells in the presence of paCDS without pDNA.  
 
The above presented experimental evidences support that the Janus paCD structures 
ADM70 and ADM105 are promising nonviral vectors for pDNA delivery, overall 
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superior  to PBO234 and to the Lipofectamine control. Differences in transfection 
efficiency as a function of the cell line might arise from differences in the preferred 
internalization routes. Thus, it has been reported that CDplexes can enter the cell by 
caveolae- and clathrin-mediated endocytosis, but only the first mechanism is productive 
regarding protein expression [30]. Moreover, CDplexes obtained from ADM70 seem to 
exhibit the most favourable features for in vitro gene therapy applications: high stability 
in the absence or presence of HP, homogeneous size distribution, lower impact (with 
respect to the other two paCDs) of the PC in the capacity of the CDplexes to efficiently 
mediate protein expression in cellulo, and very low cytotoxicity even at high eff 
values, and independently of the presence or not of HP. These features are in agreement 
with the previously observed superiority of ADM70 formulations in in vivo transfection 
studies [33,34]. The body of biophysical and biochemical evidences obtained in this 
work provides a pathway for the rigorous characterization of pDNA-molecular vector 
formulations in view of their optimization for gene therapy applications. Broadening 
the current database on vector structures, electrochemical and structural properties of 
their aggregates, protein corona composition and transfection efficiencies in different in 
vitro and in vivo experimental settings should fund the basis for the rational design of 
second generation candidates. Work in that direction is currently sought in our 
laboratories. 
 
4. Conclusions 
This work was aimed to provide new insights in the fascinating processes governing 
pDNA complexation by monodisperse vectors of the Janus paCD family, in an attempt 
to delineate the mechanisms whereby differences in molecular structure translates into 
differences in transfection capabilities. For that purpose, three Janus CD-based 
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compounds (ADM70, ADM105 and PBO234) have been thoroughly checked as 
potential nanocarriers of a pEGFP-C3 plasmid that codes for GFP expression to the 
interior of HeLa and MCF-7 cancer cells, both in the absence and presence of human 
serum. In a first level of organization, the vector molecular structure influences the 
effective positive charge available for interacting with the plasmid as well as the 
effective negative charge of the plasmid in the nanoaggregates. In fact, zeta potential 
study revealed that effective charges are lower than nominal ones both for the CD-
based vectors (around 30% for ADMs and 25% for PBO234), and also for the pDNA, 
which renders a low percentage of its negative charge (less than 15%) when it is 
compacted by the nanocarriers. This is a potentially favourable finding since the weaker 
the anionic character of the DNA, the lower the amount of cationic vector needed to 
formulate the nanocomplexes, thus decreasing the cytotoxicity of the vector and 
increasing their potential output as safe and effective vehicles of nucleic acids. On the 
other hand, SAXS and cryo-TEM studies have shown that ADM70-pDNA, ADM105-
pDNA and PBO234-pDNA CDplexes are structured according to a multilamellar 
lyotropic liquid crystal phase (L. Two different multilamellar phases are 
distinguished, nonetheless, on cryo-TEM micrographs (CT-type and FP-type 
nanoaggregates), in coexistence with unilamellar vesicles of self-aggregated exceeding 
paCDs without pDNA compacted. Although the Janus feature seems to warrant a 
multilamellar arrangement for the paCD-pDNA nanocomplexes in all cases, their 
stability and homogeneity can be significantly different depending on the topology of 
the multivalent cationizable domain in the paCD entity. In the presence of human 
plasma, a second level of organization takes place involving the interaction with serum 
proteins, giving rise to multicomponent nanoassemblies equipped with a protein corona 
whose composition varies from a paCD formulation to another. The protein corona 
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(PC) characterization has also driven to interesting conclusions. The adsorbed proteins 
have mostly a negative charge in all the cases (pI < 7), pointing to the electrostatic 
interactions as the driven non-covalent forces between proteins and the cationic vectors. 
Complement, lipoprotein and coagulation were found to be the most abundant types of 
proteins within the corona of the Janus paCDs and the corresponding CDplexes, 
whereas immunoglobulins, tissue leakage and acute phase proteins constituted a minor 
fraction of the PC. At moderate-to-high charge ratios (eff = 25 and 50), the bare 
CDplexes herein reported seem to transfect either HeLa or MCF-7 cancer cells more 
efficiently than Lipofectamine, and with high cell viabilities ranged from 80 to 100%.  
These transfection efficiencies were found to slightly decrease in the presence of 
biological media (HP), but in any case the values found were higher than those obtained 
with the control Lipofectamine. However, the effect of PC on the cell viability of 
CDplexes is not that easy to interpret. Probably, the specific PC composition and, in 
turn, its complex effect on nanocarrier processing by cell machinery, play a crucial role, 
although an  accurate mapping of protein binding sites in the PC would be necessary to 
go further in these conclusions. In any case, the whole body of both biophysical and 
biochemical evidences obtained in this work allow us to conclude that the three paCDs 
proposed can be considered as potentially efficient nanocarriers in vitro and promising 
gen vectors for in vivo applications. Going further, among the three Janus paCDS 
nanovectors checked in this work, ADM70 seem to exhibit the most favourable features 
for in vitro gene therapy applications requiring serum-containing media, in total 
agreement with the already observed superiority of ADM70 formulations in in vivo 
transfection studies.  
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Highlights 
- Effective charges (lower than nominal) potentially improve CDplexes transfection 
outputs. 
- CDplexes show L multilamellar patterns, quite appropriate to interact with cellular 
membranes. 
- When exposed to human plasma CDplexes are covered by a rich protein corona. 
- Optimized CDplexes exhibit high TE and very low cytotoxicity in HeLa and MCF7 
cancer cells. 
- TE/cell viability outputs of optimized CDplexes overcome those of the standard 
Lipofectamine. 
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